Supplemental Information to Include With QR Code

Pharmacodynamics

TAC-001 Elicits Activation of Peripheral B cells at All Dose Levels

- Consistent with proposed MOA, preliminary data demonstrates TAC-001 upregulates expression of CD40 co-stimulatory marker on naïve and memory B cells

TAC-001 Triggers TLR9 Signaling Leading to B-Cell Activation



IRF, interferon regulatory factor; NF-κB, nuclear factor-κB. Created with BioRender.com.

Increased Expression of CD40 Observed on Circulating Naïve and Memory B Cells



Peak CD40 expression in peripheral blood was assessed post-first dose up to Day 15 pre-second dose..

Pharmacodynamics

TAC-001 Elicits Production of Cytokines and Chemokines



IRF, interferon regulatory factor; NF-κB, nuclear factor-κB. Created with BioRender.com.

Cytokine and Chemokine Production Observed in Serum Samples



Serum cytokines and chemokines were assessed at pre-dose, 3, 8, and 24 hours post post–first dose. Arrows represent dose days. IL, interleukin; IP, interferon gamma-induced protein; MCP, monocyte chemoattractact protein; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor.

Patient Disposition and Baseline Characteristics

Patient Disposition

Discontinuations, n (%)	Total (n=18)
Patients discontinuing treatment	10 (56%)
Reasons for discontinuation	
Progressive disease	8 (44%)
Adverse event	1 (6%)
Withdrawal by subject	1 (6%)

Data cut-off date: 08Sep2023

Patient Baseline Characteristics: Tumor Types

Primary Cancer Diagnosis, n (%)	Total (n=18)
Colorectal carcinoma	9 (50%)
Ovarian carcinoma	2 (11%)
Cutaneous melanoma	2 (11%)
Head and neck squamous cell carcinoma	2 (11%)
Cholangiocarcinoma	2 (11%)
Gastro-esophageal carcinoma	1 (6%)

Pharmacokinetics

TAC-001 Pharmacokinetic Parameter Summary at Cycle 1, Day 1

Dose (mg/kg)	n	C_{max} (µg/mL)[a]	AUC_{last} (h*µg/mL)[a]
0.1	1	1.74	6.28
0.3	1	5.04	44.90
1	7	17.9 (5.3)	205 (78.4)
3	6	52.8 (18.2)	532 (163.0)

AUC_{last}, area under the concentration versus time curve from dosing to last measurable concentration; C_{max}, maximum plasma concentration.
[a]Mean values shown; standard deviation shown for 1 and 3 mg/kg dose group.

Safety

Safety Summary at All Dose Levels

n (%)	0.1 mg/kg (n=1)		0.3 mg/kg (n=1)		1 mg/kg (n=7)		3 mg/kg (n=9)		Total (n=18)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
TEAEs	1 (100)	0	1 (100)	0	7 (100)	5 (71.4)	9 (100)	4 (44.4)	18 (100)	9 (50)
Related TEAEs	1 (100)	0	1 (100)	0	7 (100)	1 (14.3)	8 (88.9)	2 (22.2)	17 (94.4)	3 (16.7)
DLTs[a]	0	0	0	0	0	0	1 (11.1)	1 (11.1)	1 (5.6)	1 (5.6)
TEAEs leading dose reduction/interruption	0	0	0	0	2 (28.6)	2 (28.6)	2 (22.2)	1 (11.1)	4 (22.2)	3 (16.7)
Related TEAES leading to dose reduction/interruption	0	0	0	0	1 (14.3)	1 (14.3)	1 (11.1)	1 (11.1)	2 (11.1)	2 (11.1)
Serious TEAEs	0	0	0	0	3 (42.9)	3 (42.9)	4 (44.4)	3 (33.3)	7 (38.9)	6 (33.3)
Related SAEs	0	0	0	0	1 (14.3)	1 (14.3)	1 (11.1)	1 (11.1)	2 (11.1)	2 (11.1)

TEAE, treatment-emergent adverse event; DLT, dose-limiting toxicity; SAE, serious adverse event.
[a]DLT was Grade 3 immune-mediated hepatoxicity observed at 3.0 mg/kg; No treatment-related fatal events were observed at any dose level
Data cut-off date: 08Sep2023